These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33744986)

  • 1. Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
    Vermunt MAC; van der Heijden LT; Hendrikx JJMA; Schinkel AH; de Weger VA; van der Putten E; van Triest B; Bergman AM; Beijnen JH
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):855-869. PubMed ID: 33744986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
    Vermunt MAC; Robbrecht DGJ; Devriese LA; Janssen JM; Thijssen B; Keessen M; van Eijk M; Kessels R; Eskens FALM; Beijnen JH; Mehra N; Bergman AM
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1367. PubMed ID: 33709626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
    Vermunt MAC; de Weger VA; Janssen JM; Lopez-Yurda MI; Keessen M; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Marchetti S
    Drugs R D; 2021 Mar; 21(1):103-111. PubMed ID: 33464545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.
    de Weger VA; Stuurman FE; Hendrikx JJMA; Moes JJ; Sawicki E; Huitema ADR; Nuijen B; Thijssen B; Rosing H; Keessen M; Mergui-Roelvink M; Beijnen JH; Schellens JHM; Marchetti S
    Eur J Cancer; 2017 Nov; 86():217-225. PubMed ID: 29031170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir.
    de Weger VA; Stuurman FE; Koolen SLW; Moes JJ; Hendrikx JJMA; Sawicki E; Thijssen B; Keessen M; Rosing H; Mergui-Roelvink M; Huitema ADR; Nuijen B; Beijnen JH; Schellens JHM; Marchetti S
    Clin Cancer Res; 2019 Sep; 25(18):5466-5474. PubMed ID: 31217201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
    Yu H; Janssen JM; Sawicki E; van Hasselt JGC; de Weger VA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR
    J Clin Pharmacol; 2020 Mar; 60(3):340-350. PubMed ID: 31595980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
    Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir.
    Yu H; Janssen JM; de Weger VA; Nuijen B; Stuurman RE; Marchetti S; Schellens JHM; Beijnen JH; Dorlo TPC; Huitema ADR
    Invest New Drugs; 2020 Oct; 38(5):1526-1532. PubMed ID: 32306204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.
    de Vries Schultink AHM; Crombag MBS; van Werkhoven E; Otten HM; Bergman AM; Schellens JHM; Huitema ADR; Beijnen JH
    Cancer Med; 2019 Apr; 8(4):1406-1415. PubMed ID: 30802002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
    Thakur MK; Heilbrun L; Dobson K; Boerner J; Stark K; Li J; Smith D; Heath E; Fontana J; Vaishampayan U
    Clin Genitourin Cancer; 2018 Jun; 16(3):e695-e703. PubMed ID: 29534939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.
    de Weger VA; Vermunt MAC; Stuurman FE; Burylo AM; Damoiseaux D; Hendrikx JJMA; Sawicki E; Moes JJ; Huitema ADR; Nuijen B; Rosing H; Mergui-Roelvink M; Beijnen JH; Marchetti S
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):607-621. PubMed ID: 33021083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.
    Crombag MBS; Dorlo TPC; van der Pan E; van Straten A; Bergman AM; van Erp NP; Beijnen JH; Huitema ADR
    Pharm Res; 2019 Nov; 36(12):181. PubMed ID: 31732882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.